![]() ![]() “All of the work being done by Tessera and across the field will result in better health outcomes for patients around the world. The transaction included participation from existing investors Alaska Permanent Fund, Altitude Life Science Ventures, new investors a wholly-owned subsidiary of the Abu Dhabi Investment Authority, ARTIS Ventures, Cormorant Asset Management, LP, Flagship. 2022 News From Big Pharma to little Tessera Michael Severino rewrites his. ![]() The company has received more than 300,000,000 in the transaction. Biotech News and Research Shukra Pharmaceuticals Ltd Live BSE Share Price. “This is an amazing time for the field of genetic medicine,” von Maltzahn said. On April 19, 2022, Tessera Therapeutics, Inc. ![]() When asked if an IPO could be next, Liang responded: “We’re formulating a financing plan for the company, but I think we as a company are quite ambitious, so I’m sure we’ll work with partners on the capital market,” and added that he’s open to “other means to help finance the company.” But even so, it was able to secure a massive $230 million Series B round back in January. Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with 230 million in new financing Programmable genetics gets more cash as. The team hasn’t yet announced a timeline to the clinic (Prime says it’s still years away). “This is not just a hot idea, but really a lot of great work has been done.” “I would say that the team is one of the most important attractions at Tessera,” he said. Little more than a year after it raised a 230 million Series B round, Flagship Pioneering spinout Tessera Therapeutics has raised another 300 million that it intends to funnel into. Now he wanted to do something on the “cutting edge of science.” And he knew the Flagship team very well - after all, they are just two floors away from his old office at BeiGene. The CFO got his start as a senior scientist at Abbott Laboratories, then spent a good portion of his career on Wall Street before jumping back into the industry. This approach is much different from CRISPR 1.0, which the CEO compared to scissors that destroy invasive DNA.Īfter spending six years at BeiGene, Liang said he was ready for something different. Tessera is a biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology. About Tessera TherapeuticsTessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and doctors the ability to write. “This technology involves RNA-only delivery and enables Tessera to both add new functions to the genome and fix disease-causing mutations.” The Life Sciences team advised Tessera Therapeutics on its Series C financing, which totaled over 300 million. “In particular, we have been focused on engineering retrotransposons, which write DNA into the genome via a process called target primed reverse transcription,” von Maltzahn said via email. ![]()
0 Comments
Leave a Reply. |